Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 7
1977 2
1978 5
1979 3
1980 2
1981 3
1982 6
1983 5
1984 13
1985 5
1986 5
1987 3
1988 8
1989 5
1990 4
1991 9
1992 12
1993 7
1994 5
1995 7
1996 7
1997 4
1998 5
1999 6
2000 10
2001 13
2002 11
2003 8
2004 4
2005 6
2006 6
2007 3
2008 6
2009 6
2010 5
2011 3
2012 8
2013 6
2014 13
2015 10
2016 3
2017 4
2018 2
2019 2
2022 1
2024 2
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

255 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials.
Cholesterol Treatment Trialists' (CTT) Collaboration; Fulcher J, O'Connell R, Voysey M, Emberson J, Blackwell L, Mihaylova B, Simes J, Collins R, Kirby A, Colhoun H, Braunwald E, La Rosa J, Pedersen TR, Tonkin A, Davis B, Sleight P, Franzosi MG, Baigent C, Keech A. Cholesterol Treatment Trialists' (CTT) Collaboration, et al. Lancet. 2015 Apr 11;385(9976):1397-405. doi: 10.1016/S0140-6736(14)61368-4. Epub 2015 Jan 9. Lancet. 2015. PMID: 25579834 Free article.
The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials.
Cholesterol Treatment Trialists' (CTT) Collaborators; Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH, Voysey M, Gray A, Collins R, Baigent C. Cholesterol Treatment Trialists' (CTT) Collaborators, et al. Lancet. 2012 Aug 11;380(9841):581-90. doi: 10.1016/S0140-6736(12)60367-5. Epub 2012 May 17. Lancet. 2012. PMID: 22607822 Free PMC article.
Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis.
Cholesterol Treatment Trialists’ (CTT) Collaboration. Electronic address: [email protected]; Cholesterol Treatment Trialists’ (CTT) Collaboration. Cholesterol Treatment Trialists’ (CTT) Collaboration. Electronic address: [email protected], et al. Lancet Diabetes Endocrinol. 2024 May;12(5):306-319. doi: 10.1016/S2213-8587(24)00040-8. Epub 2024 Mar 27. Lancet Diabetes Endocrinol. 2024. PMID: 38554713 Free PMC article.
Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials.
Cleland JGF, Bunting KV, Flather MD, Altman DG, Holmes J, Coats AJS, Manzano L, McMurray JJV, Ruschitzka F, van Veldhuisen DJ, von Lueder TG, Böhm M, Andersson B, Kjekshus J, Packer M, Rigby AS, Rosano G, Wedel H, Hjalmarson Å, Wikstrand J, Kotecha D; Beta-blockers in Heart Failure Collaborative Group. Cleland JGF, et al. Among authors: wikstrand j. Eur Heart J. 2018 Jan 1;39(1):26-35. doi: 10.1093/eurheartj/ehx564. Eur Heart J. 2018. PMID: 29040525 Free PMC article.
Long-term cardiovascular risks and the impact of statin treatment on socioeconomic inequalities: a microsimulation model.
Wu R, Williams C, Zhou J, Schlackow I, Emberson J, Reith C, Keech A, Robson J, Armitage J, Gray A, Simes J, Baigent C, Mihaylova B; CTT Collaboration secretariat CTT Collaboration trialists: A to Z trial (phase Z) AFCAPS/TEXCAPS (AirForce/Texas Coronary Atherosclerosis Prevention Study)ALERT (Assessment of Lescol in Renal Transplantation)ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial)ALLIANCE (Aggressive Lipid-Lowering Initiation Abates New Cardiac Events)ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial)ASPEN (Atorvastatin Study for the Prevention of Coronary Heart Disease Endpoints in Non-Insulin Dependent Diabetes Mellitus)AURORA (A study to evaluate the Use of Rosuvastatin in subjects On Regular haemodialysis: an Assessment of survival and cardiovascular events)CARDS (Collaborative Atorvastatin Diabetes Study)CARE (Cholesterol And Recurrent Events Study)CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure)4D (Die Deutsche Diabetes Dialyse Studie)GISSI (Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico) Heart Failure and Prevention trialsHOPE-3HPS (Heart Protection Study)IDEAL (Incremental Decrease in E… See abstract for full author list ➔ Wu R, et al. Br J Gen Pract. 2024 Feb 29;74(740):e189-e198. doi: 10.3399/BJGP.2023.0198. Print 2024 Mar. Br J Gen Pract. 2024. PMID: 38373851 Free PMC article.
MERIT-HF--description of the trial.
Wikstrand J. Wikstrand J. Basic Res Cardiol. 2000;95 Suppl 1:I90-7. doi: 10.1007/s003950070016. Basic Res Cardiol. 2000. PMID: 11192361 Review.
255 results